1.53
Outlook Therapeutics Inc stock is traded at $1.53, with a volume of 132.07K.
It is down -1.61% in the last 24 hours and up +8.93% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.55
Open:
$1.57
24h Volume:
132.07K
Relative Volume:
0.27
Market Cap:
$47.30M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.3825
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
+5.17%
1M Performance:
+8.93%
6M Performance:
-71.97%
1Y Performance:
-81.38%
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
OTLK
Outlook Therapeutics Inc
|
1.53 | 47.30M | 0 | -51.50M | -47.10M | -4.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.08 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
596.99 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
609.69 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.17 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
247.49 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
Jul-13-23 | Initiated | CapitalOne | Overweight |
Apr-03-23 | Initiated | Guggenheim | Buy |
Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-31-22 | Initiated | BTIG Research | Buy |
Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
May-16-19 | Initiated | Oppenheimer | Outperform |
Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - ADVFN
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
25,615 Shares in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Acquired by Commonwealth Equity Services LLC - Defense World
Outlook Therapeutics Approves Retention Incentive for CFO - MSN
Henlius And Outlook Move Forward With Ophthalmic Bevacizumab - insights.citeline.com
Guggenheim maintains Buy on Outlook Therapeutics, target $10 By Investing.com - Investing.com Canada
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
FDA accepts updated biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD - Optometry Times
Guggenheim maintains Buy on Outlook Therapeutics, target $10 - Investing.com
FDA sets August 27 review date for Outlook Therapeutics’ eye drug By Investing.com - Investing.com South Africa
Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA ResubmissionSEC Filing - marketscreener.com
Outlook Therapeutics (OTLK) Soars After FDA Accepts ONS-5010 for Review - GuruFocus
OTLKWOutlook Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Outlook Therapeutics gets FDA review acceptance for wet AMD treatment - Seeking Alpha
Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment - MarketScreener
FDA sets August 27 review date for Outlook Therapeutics' eye drug - Investing.com
FDA sets August 27 review date for Outlook Therapeutics’ eye drug - Investing.com India
Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD - Nasdaq
Outlook Therapeutics® Announces Acceptance of Biologics - GlobeNewswire
Major FDA Milestone: Novel Wet AMD Drug Gets Review Date, Could Be First-of-its-Kind Approval - Stock Titan
Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World
Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com
Outlook Therapeutics expands share authorization - Investing.com Australia
Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks
Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK
Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire
Outlook Therapeutics® Re-Submits Biologics License - GlobeNewswire
Outlook Therapeutics Resubmits BLA For ONS-5010, A Proposed Treatment For Wet AMD - Nasdaq
Outlook Therapeutics Resubmits Biologics License Application By Investing.com - Investing.com South Africa
Outlook Therapeutics Resubmits BLA For ONS-5010 To FDA In Wet AMD - Nasdaq
Outlook Therapeutics Resubmits Biologics License Application - Investing.com
Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - StockTitan
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 – OTLK - ACCESS Newswire
Outlook Therapeutics (NASDAQ:OTLK) Given New $24.00 Price Target at Ascendiant Capital Markets - Defense World
HC Wainwright Issues Pessimistic Forecast for OTLK Earnings - MarketBeat
Equities Analysts Offer Predictions for OTLK Q1 Earnings - MarketBeat
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World
What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):